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Untargeted metabolomics reveals a 
new mode of action of pretomanid 
(PA-824)
Rafael Baptista  1, David M. Fazakerley1, Manfred Beckmann1, Les Baillie2 & Luis A. J. Mur  1
Pretomanid is a promising anti-tubercular drug currently at clinical phase III, but its mechanisms 
of action are currently unclear. This study aimed to: (i) reveal the metabolome of Mycobacterium 
smegmatis under pretomanid treatment; (ii) compare major sources of metabolite variation in bacteria 
treated with pretomanid treatment and other antibiotics; and (iii) to target metabolites responsible 
for the killing activity of pretomanid in mycobacteria. Untargeted high-resolution metabolite profiling 
was carried out using flow infusion electrospray ion high resolution mass spectrometry (FIE-HRMS) to 
identify and quantify metabolites. The identification of key metabolites was independently confirmed 
by gas-chromatography time-of flight mass spectrometry (GC-tofMS) in comparison to standards. 
Pretomanid treatments generated a unique distinctive metabolite profile when compared to ampicillin, 
ethambutol, ethionamide, isoniazid, kanamycin, linezolid, rifampicin and streptomycin. Metabolites 
which differed significantly only with pretomanid treatment were identified and mapped on to bacterial 
metabolic pathways. This targeted the pentose phosphate pathway with significant accumulation seen 
with fructose-6-phosphate, ribose-5-phosphate and glyceraldehyde-3-phosphate. These effects were 
linked to the accumulation of a toxic metabolite methylglyoxal. This compound showed significant 
antimicrobial activity (MIC 0.65 mM) against M. smegmatis.
Tuberculosis (TB) persists as a major global threat, mostly amongst people infected with antibiotic resistant forms 
of Mycobacterium tuberculosis, the causal agent of the disease1. As a result, the pursuit for new anti-mycobacterials 
has accelerated in recent years. This search for anti-mycobacterials has identified the very promising bicyclic 
nitroimidazoles pretomanid (PA-824) and delamanid (OPC-67683), which are currently in clinical phase III 
with the Global Alliance for TB Drug Development. These have shown to be active against both replicative and 
hypoxic non-replicating bacilli1,2. This significant characteristic makes possible the relatively rapid elimination of 
bacteria which otherwise would require treatment for extended periods (6 to 8 months).
Studies have suggested that pretomanid could act on the mycolic acid biosynthetic pathway through depletion 
of ketoymycolates and the accumulation of hydroxymycolates2. Although this explains its anti-mycobacterial 
activity in replicative bacteria, it does not explain the activity of pretomanid against latent cells. Additionally, 
it has been shown that a des-nitroimidazole derivative from pretomanid metabolism was responsible for the 
generation of reactive nitrogen species and ATP depletion, which would explain its activity under anaerobic con-
ditions3. This des-nitro metabolite was only identified in Mycobacterium tuberculosis and not in the fast-growing 
species M. smegmatis4. The uncertainties arising from the clear multi-target profile of pretomanid, when coupled 
with it clinical promise, makes the elucidation of its mode of action an urgent imperative. Understanding the 
interaction between pretomanid and the target bacterial metabolome could be invaluable in unequivocally defin-
ing the mechanisms of action, foreseeing future resistance mechanisms, predicting potential toxicity issues and 
possibly contribute to the discovery of new TB therapeutic candidates.
To address these issues the impact of pretomanid on the M. smegmatis metabolome is here defined using 
a cutting-edge untargeted metabolomic strategy5. M. smegmatis has been extensively used as model for stud-
ies for searching new anti-mycobacterials. The use of this specific strain is due to its rapid doubling time, 
low-pathogenicity and close genetic similarity to M. tuberculosis. More importantly, the metabolic pathway 
described in this study is conserved between both species6. Rapid analysis and quantification of biological 
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signatures allowed us to not only to describe significant bacterial intracellular changes pretomanid generates 
but crucially, distinguish its mode of action. The metabolite profiles were obtained using flow infusion electro-
spray ion high resolution mass spectrometry (FIE-HRMS) and the identification of compounds of interest was 
validated by matching retention times with standards, by gas-chromatography time-of flight mass spectrometry 
(GC-tofMS).
Results and Discussion
Pretomanid treated bacteria display a distinct metabolome. The metabolite profiles of mycobac-
teria cultures in mid-log phase were obtained at 0, 2, 4, 6 h following treatment with nine antibiotics: ampi-
cillin, ethambutol, ethionamide, isoniazid, kanamycin, linezolid, rifampicin, streptomycin, pretomanid and an 
untreated control group. The concentration of antibiotic used was standardised in order to obtain 50 % of bacte-
rial growth inhibition at 6 hours, as previously proposed7 (Table S1). Mass ions associated with a given antibiotic 
or its metabolites were eliminated from the data matrix prior to multivariate statistical analysis.
Metabolomic similarities may expected in the profiles of bacteria treated with antibiotics targeting the same 
biological pathway. We observed such an effect using unsupervised principal component analysis (PCA) indi-
cated distinctive clusters for antibiotics targeting different metabolic pathways (Fig. 1). For example, antibiotics 
targeting protein and cell wall biosynthesis pathways showed distinctive clustering patterns compared to oth-
ers. Such observations confirm our assertion that untargeted metabolomics can to overcome the complexity 
and uncertainty of the available target discovery as a “stand-alone” methodology or via integration with other 
approaches, for example, transcriptomics. Crucially, bacteria treated with pretomanid displayed a different met-
abolic pattern compared to other antibiotics, suggesting that its mode of action was distinct. This significantly 
different metabolomic profile for pretomanid treatment was observed at all time-points (Fig. S1).
All bacterial metabolites that significantly differed (P < 0.05) on pretomanid treatment compared to controls 
were identified. This allowed us to identify the most prominent changes associated to a specific metabolic pathway 
following mapped on to mycobacterial metabolism as defined by KEGG. Metabolites in fatty acid metabolism, 
amino acid metabolism, pentose phosphate pathway, purine metabolism and pyrimidine metabolism were found 
to significantly differ between control and pretomanid treatment (Fig. 2). In particular, metabolites from the pen-
tose phosphate pathway accumulated on pretomanid treatment. No other major metabolic processes were shown 
to change in manners which would suggest a possible cell inhibitory mechanism. Mycolic acids were previously 
suggested as the pretomanid target2, and we also notes a large fraction of metabolites associated to fatty acid 
metabolic perturbation (Fig. 2). This could suggest a pretomanid mode of action based on altered mycolic acid 
synthesis. However, we propose alternative targets, given the distinctive PCA clusters shown in Fig. 1 which were, 
for example different from isoniazid, which inhibits mycolic acid synthesis8.
Accumulation of phosphate sugars leads to increased levels of toxic methylglyoxal. The analysis 
of rapid metabolic changes of bacteria following antibiotic treatment can occasionally be deceptive. These changes 
are adaptive and can be related to indirect effects of the drug that ultimately do not relate to cell death or cell 
Figure 1. Demonstrative principal component analysis (PCA) score plots of FIE-MS data of 2285 normalised 
m/z intensity values (P < 0.05) in both negative and positive ionisation mode, 6 h after antibiotic treatment: (A) 
AMP-ampicillin, C-control group, EMB-ethambutol, ETH-ethionamide, INH-isoniazid, KAN-kanamycin, 
LIN-linezolid, PRE-pretomanid, RIF-rifampicin, STR-streptomycin; (B) samples were clustered based on their 
mechanism of action, CW-cell wall synthesis, PS-protein synthesis, PRE-pretomanid treatment. Coloured 
regions display 95% confidence.
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division arrest mechanisms. To counter any false leads were targeted metabolites linked to crucial metabolic pro-
cesses which were conserved across all mycobacterial species. Our metabolomic data indicated that pretomanid 
treatment led to the significant (P < 0.05) accumulation of metabolites downstream from glucose-6-phosphate 
in the pentose phosphate pathway. These included of ribose-5-phosphate, fructose-6-phosphate and 
glyceraldehyde-3-phosphate, particularly at 6 h after treatment with pretomanid (Fig. 3A–C). The identity of 
ribose-5-phosphate and fructose-6-phosphate were unequivocally confirmed by GC-tofMS through comparison 
to commercially available standards, with retention times of 7.37 and 7.93 min, respectively.
These observations align with the known mechanism of activation of the prodrug pretomanid in all mycobac-
teria. Activation of pretomanid is known to involve reduction by a deazaflavin dependent nitroreductase (Ddn). 
This conversion is catalysed by the cofactor F420H2 and the reductive form of F420 is linked to the conversion 
of glucose-6-phosphate (G6P) to 6-phosphoglucolactone by glucose-6-phosphate dehydrogenase (G6PD)9–11. 
The reaction is catalysed by F420-dependent glucose-6-phosphate dehydrogenase (FGD) leading to the bio-
synthesis of ribulose-5-phosphate in the pentose phosphate pathway, further yielding ribose-5-phosphate and 
xylulose-5-phosphate and later, fructose-6-phosphate and glyceraldehyde-3-phosphate. Since the activation of 
pretomanid is F420H2-dependent, the biosynthesis of this coenzyme is an absolute requirement for its activity. The 
Figure 2. A pool of 794 putative identified metabolites that were significantly differed (P < 0.05) between 
samples from control and treatment with pretomanid were mapped on to specific metabolic pathways as defined 
by KEGG (Kyoto Encyclopaedia of Genes and Genomes). The Sankey diagram shows the relative accumulation 
of metabolites per pathway. Only pathways where more than three constituent metabolites have been targeted 
are depicted as discrete pathways. The associated heatmap schematically represents the relative concentration 
of each metabolite in six replicates of untreated controls and pretomanid-treated (t = 6 h) Mycobacterium 
smegmatis cultures.
Figure 3. Accumulation of ribose-6-phosphate (A), glyceraldehyde-3-phosphate (B), fructose-6-phosphate 
(C) and methylglyoxal (D) at 6 h in M. smegmatis under pretomanid treatment (triangle) and control samples 
(circle). Log10 normalisation using logarithmic transformation of data. **P < 0.01, ***P < 0.001.
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only way to obtain this coenzyme is by the conversion of glucose-6-phosphate into 6-phosphoglucolactone, which 
will trigger an accumulation of downstream sugar phosphates.
The consequences of the accumulation of phosphate sugars, such as fructose-6-phosphate, have been studied 
in the context of bacterial metabolism in E. coli. The cessation of growth and loss of cell viability has been assumed 
to be due to the accumulation of methylglyoxal, which is produced as the result of the intracellular accumulation 
glucose-6-phosphate and fructose-6-phosphate12,13. This highly reactive aldehyde induces toxicity based on the 
interaction with proteins/amino acids and DNA/nucleotides, leading to the accumulation of glycated products 
and resultant cell arrest14–16. As a result, methylglyoxal intracellular production should be maintained within a 
certain range otherwise the bacteria’s electrophile protection mechanisms fail, leading to cell arrest17. This obser-
vation also aligns with the observations of Noy et. when examining the regulation of the glycolytic pathway 
in M. tuberculosis. Pyruvate kinase (encoded by pykA) catalyzes the rate-limiting step in glycolysis and pykA, 
mutated strains were not viable when grown on such as glucose. Analyses of the pykA, mutants showed that the 
shifts in metabolism included glucose-6-phosphate diversion toward ribulose-5-phosphate and the production of 
methylglyoxal18. Within a mammalian context, methylglyoxal is known to induce apoptosis in different cell lines 
by interfering with glutathione metabolism to hinder the neutralisation of oxidative radicals19.
Given this, the accumulation of methylglyoxal that was detected at 6 h after pretomanid treatment (Fig. 3D) 
was a significant observation. We took pains to confirm the identity of the methylglyoxal ions in a follow-up 
experiment where FIE-HRMS was conducted with samples spiked with the commercially available standard (Fig. 
S2). The relative accumulation of methylglyoxal compared to controls was not seen when M. smegmatis is treated 
with any other antibiotic, confirming this as a unique mode of action of pretomanid (Fig. 4). To confirm the influ-
ence of methylglyoxal in mycobacterial growth, the MIC of this compound against M. smegmatis was measured 
(Fig. 5). Methylglyoxal was shown to be toxic at a MIC of 0.65 mM, being in line with previous results obtained 
against the pathogenic strain M. tuberculosis13. This modest MIC is likely to be due to difficulties in bacterial 
cell internalisation. Nevertheless, this result confirms the toxic effect of methylglyoxal in mycobacteria due to 
overloading the pentose phosphate pathways (Fig. 6). The importance of this metabolic pathway establishes that 
our observations in M. smegmatis will be of relevance to the slower growing M. tuberculosis. Further, the known 
effects of methylglyoxal accumulation14–16 is likely to explain the wider effects on metabolite changes in amino 
acid, purine and pyrimidine metabolism (Fig. 2), The increased levels of methylglyoxal would only have reper-
cussions in bacterial cells, since the enzyme Ddn is only present in Mycobacterium and other Actinobacteria, 
except M. leprae20. This further suggests, to a certain extent, the safety of pretomanid for human use. Clearly, our 
Figure 4. Accumulation of methylglyoxal in M. smegmatis is only visible under pretomanid treatment. 
AMP-ampicillin, EMB-ethambutol, ETH-ethionamide, INH-isoniazid, KAN-kanamycin, LIN-linezolid, PRE-
pretomanid, RIF-rifampicin, STR-streptomycin. Log10 normalisation using logarithmic transformation of data. 
Data are means ± SD. **P < 0.01.
Figure 5. M. smegmatis growth inhibition by methylglyoxal, at 0.33, 0.43 and 0.65 mM, over 48 h.
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conclusions needs to be substantiated by in vivo studies based on such as macrophage infection models where the 
effects of for example, hypoxia on methylgloxal accumulation can be assessed.
High resolution metabolomic profiling; a new approach for drug mode of action studies. Using 
robust and reproducible information has allowed us to comprehend the mechanism of action of pretomanid 
against Mycobacterium. By applying metabolomics we were able to show that pretomanid has a distinctive mode 
of action different from other currently known antibiotics. We have also gained insights into its specific mode of 
action, disrupting normal cell sugar phosphate metabolism leading to the accumulation of toxic methylglyoxal. 
This proposed mechanism would be effective against both replicative and latent Mycobacteria. Henceforth, it is 
expected these conclusions will provide deeper insights not only into the metabolism of mycobacterial strains 
resistant to pretomanid, but also in the use of the discovered biosynthetic pathway, the pentose phosphate’s accu-
mulation and in the rational development of new anti-tubercular molecules.
Materials and Methods
Chemicals. Pretomanid, streptomycin sulfate, ethambutol dihydrochloride, ethionamide, isoniazid, line-
zolid and standards (glucose-6-phosphate, ribose-5-phosphate, fructose-6-phosphate and methylglyoxal) were 
obtained from Sigma. Kanamycin sulfate, ampicillin sodium salt and rifampicin were obtained from Gibco, 
Melford and Duchefa Biochemie respectively.
Bacterial growth conditions. All the procedures were carried out in a biosafety containment level 2. 
Mycobacterium smegmatis strain was purchased from National Health England (ATCC 19420) and used for test-
ing all the compounds. M. smegmatis, rapidly growing mycobacteria, was cultured in Luria-Bertani (LB) medium 
supplemented with 0.2% (v/v) glycerol and 0.05% (v/v) of Tween 80 at 37 °C with aeration at 200 rpm until OD600 
0.6 was reached.
Determination of in vitro antibacterial activity and dosage for metabolomics. The minimum 
inhibitory concentration (MIC) of methylglyoxal was determined using broth microdilution method, in 96-well 
plate format, in fresh LB medium. All samples were tested in triplicate in an initial bacterial concentration of 
5.0 × 105 CFU/mL. The MIC was determined as the lowest concentration of a drug at which no growth was visible 
after 48 h. The optical density OD600 was measured in a Hidex plate spectrophotometer.
To access the concentration of antibiotics required to inhibit the bacterial growth by 50%, a microdilution of 
all antibiotics in a bacterial culture of OD600 0.6 was performed. The optical density OD600 was measured after 6 h 
of treatment. The dosage of antibiotic to use in the metabolomic protocol was then calculated.
Sample preparation and metabolite extraction for FIE-HRMS and GC-tofMS. The bacterial incu-
bation throughout the sampling consisted in constant shaking at 200 rpm at 37 °C. Six biological replicates of each 
isolate treated with antibiotic and the untreated control group were independently cultured.
All samples were collected during mid-exponential growth phase. A 10 mL aliquot of bacterial culture (OD600 
at time 0 h was 0.6) was harvested at 0, 2, 4 and 6 h after the treatment with the respective antibiotic. The samples 
were stored at −80 °C after the cellular metabolism was rapidly quenched with liquid N2. After thawing, the sam-
ples were centrifuged at 10 °C at 4500 rpm. The yielded pellet was then washed with 10 mL of cold saline solution 
(0.85 % NaCl) with consequent centrifugation at 10 °C at 4500 rpm. All samples were adjusted to an OD600 of 1 
before the extraction with 200 μL of a chloroform/methanol/water (1:3:1) solution. The extraction was achieved by 
four freeze-thaw cycles with periodic vortexing. After a final centrifugation at 4500 rpm, 170 μL of the particle-free 
supernatant was transferred into a microcentrifuge tube. An additional extraction with 180 of chloroform/metha-
nol/water (1:3:1) was done and the new supernatant, after final centrifugation, was combined with the supernatant 
from the first extraction. From this mixture, 50 μL were transferred into a HPLC vial containing a 0.2 mL flat bot-
tom micro insert for FIE-HRMS analysis; the remaining volume (~120 μL) was transferred into a 1.5 mL micro-
centrifuge tube and evaporated under vacuum (UniEquip UNIVAPO 150 H, UK) for further GC-tofMS analysis.
Figure 6. Pentose phosphate pathway. Pretomanid induces the conversion of glucose-6-phosphate in 
6-phosphogluconolactone and consecutively the accumulation metabolites downstream the pentose phosphate 
pathway. G6PD - glucose-6-phosphate dehydrogenase, Ddn - deazaflavin dependent nitroreductase. The 
associated heatmap schematically depicts the relative concentration of each metabolite in six replicates of 
untreated controls and t = 6 h pretomanid-treated Mycobacterium smegmatis liquid cultures.
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Metabolite profiling by GC-tofMS analysis. For gas chromatography time-of-flight mass spectrometry 
(GC-tofMS) dried samples were derivatized first by methoximation using 5 μL of a 20 mg mL−1 solution of meth-
oxyamine hydrochloride (Fluka) in pyridine (Fluka) at 30 °C for 90 min to protect carbonyl moieties. Acidic pro-
tons were subsequently derivatized with 10 μL N-methyl-N-trimethylsilyltrifluoride (MSTFA, M&N) at 37 °C for 
30 min. Derivatized samples were transferred into 200 μL glass vials (Chromacol) and 1 μL was injected split-less 
into a Leco Pegasus III GC-tofMS system (St. Joseph, USA) equipped with an Agilent 6890 N gas chromato-
graph equipped with a 20 m DB5-MS column (0.25 mm ID, 0.25μm film) and a Focus autosampler (Anatune, 
UK). Injector temperature was 250 °C, the interface was set to 260 °C and the ion source temperature held at 
230 °C. Helium flow was 1.4 mL min−1. After 1 min at 80 °C, oven temperature was increased by 30 °C min−1 to 
330 °C, held at 330 °C for 3 min and cooled to 80 °C. Automated deconvolution and peak finding was performed 
using ChromaTof software (Leco, St. Joseph, USA) and peak alignment was carried out in MATLAB (V6.5.1, The 
MathWorks).
Metabolite fingerprinting by flow injection electrospray high resolution mass spectrometry 
(FIE-HRMS). Flow infusion electrospray high-resolution mass spectrometry (FIE-HRMS) was performed 
using an Exactive HCD mass analyser equipped with an Accela UHPLC system (Thermo-Scientific) which gen-
erated metabolite fingerprints in both, positive and negative ionisation mode, in a single run. Samples (20 µL 
volume) were injected into a flow of 100 µl.min−1 methanol: water (70:30, v/v). Ion intensities were acquired 
between m/z 50 and 1000 for 3.5 min at a resolution setting of 100,000 (at m/z 200) resulting in 3 ( ± 1) ppm mass 
accuracy. ESI source parameters were set according to manufacturer’s recommendations. Raw files were exported 
to CDF-files, mass aligned and centroided in MATLAB (V8.2.0, The MathWorks) maintaining highest mass accu-
racy. Mass spectra around the apex of the infusion peak were combined in a single intensity matrix (runs x m/z) 
for each ion mode. Data from intensity matrix was log-transformed before further statistical analysis.
Metabolomic data analysis. Univariate and multivariate analyses were performed with MetaboAnalyst 
3.0. Differences in the metabolomics profiles of samples were analysed with unsupervised PCA (principal com-
ponent analysis) and supervised PLS-DA (partial least-squares discriminant analysis). The significance of the 
cross-validated P-values, based on one-way analysis of variance (ANOVA), was set to P < 0.05. Multiple com-
parison and post hoc analysis used Tukey’s Honestly Significant Difference (Tukey’s HSD). Both ANOVA and 
Tuckey’s HSD allowed the identification of significant metabolite changes between groups (control or antibi-
otics). Metabolites that did not show significant differences between treatment and control were not further 
analysed. For each mass,-ion (m/z) the annotation was made using a 3 ppm tolerance on their accurate mass. 
Metabolomic annotation was made using MZedDB21 (http://maltese.dbs.aber.ac.uk:8888/hrmet/index.html), 
the E. coli Metabolome Database (ECMDB, http://ecmdb.ca/) and LipidMaps (http://www.lipidmaps.org/) 
databases, considering the following possible adducts: [M + H] + , [2 M + H] + , [M + 2 H]2 + , [M + 3 H] + , 
[M + Na] + , [M + Na + 2 H] + , [2 M + Na] + , [M + 2Na−H] + , [M + 2Na + H] + , [M + Na + H]2 + , 
[M + 2Na] + , [M + 3Na]3 + , [M + K] + , [M + K + H]2 + , [M + 2 K + H] + , [M−FA + H] + , [M−
H2O + H] + , [2 M + 3H2O + 2 H]2 + , [M + NH4] + , [M + NH4 + H] + , [M + NH4 + H]2 + , [2 M + NH4] + , 
[M + ACN + H] + , [M + ACN + Na] + , [2 M + ACN + H] + , [M + ACN + 2 H] + , [M + 2ACN]2 + , 
[M + 2ACN + H] + , [M + 2ACN + 2 H] + , [M + 3ACN + 2 H] + , [M + ACN + Na] + , [M + CH3OH + H] + ; 
[M−H]−, [2M−H]−, [3M−H]−, [M−2H]−, [M−3H]−, [M−H2O−H]−, [M + Cl]−, [M + FA−H]−, 
[2 M + FA−H]−, [M + Hac−H]−, [M + Na−2H]−, [2 M + Na−2H]−, [M + K−2H]−, [M + TFA−H]−. The 
targeted metabolites were mapped on to Kyoto Encyclopedia of Genes and Genomes (KEGG) for pathway analy-
sis (http://www.genome.jp/kegg/pathway.html).
For definitive metabolite identification, the retention time of standards (glucose-6-phopshate, ribose-
5-phosphate and fructose-6-phosphate) was analysed by gas chromatography time-of-flight mass spectrometry. 
Methylglyoxal was identified by overlay of spiked samples injected in FIE-MS; the tolerance on the accurate mass 
for the peak annotation was 1 ppm.
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